Related Experiment Video
Updated: Jul 18, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
U.S. regulatory perspective on the minimal clinically important difference in chronic obstructive pulmonary disease
1Office of Drug Evaluation II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Room 13B-28, HFD-102, 5600 Fishers Lane, Rockville, Maryland 20857, USA. meyerro@cder.fda.gov
COPD
|December 2, 2006
Summary
This paper examines regulatory challenges in using minimally clinically important differences (MCID) for chronic obstructive pulmonary disease (COPD) treatments. It reviews current COPD therapies and their approval, focusing on MCID
Area of Science:
- Pulmonology and Respiratory Medicine
- Clinical Trial Design and Regulatory Science
Background:
- Chronic obstructive pulmonary disease (COPD) treatments require robust outcome assessment.
- Regulatory agencies face challenges in defining and applying minimally clinically important differences (MCID).
- Understanding current and emerging COPD therapies is crucial for context.
Purpose of the Study:
- To outline regulatory issues concerning the determination and use of MCID in COPD.
- To review current US-approved COPD therapies and their regulatory pathways.
- To discuss the application of MCID in assessing COPD treatment outcomes from a regulatory standpoint.
Main Methods:
- Review of US-approved drug therapies for COPD.
- Analysis of regulatory perspectives on MCID in clinical trial outcome assessment.
- Discussion of MCID determination and application in COPD treatment evaluation.
Main Results:
- The paper details the current landscape of approved COPD therapies and their approval processes.
- It highlights the complexities and inconsistencies in applying MCID across different COPD treatments.
- The U.S. regulatory experience with MCID in outcome assessment for COPD is presented.
Conclusions:
- Standardized MCID determination is essential for consistent evaluation of COPD treatments.
- Regulatory clarity on MCID use is needed to ensure meaningful clinical benefit assessment.
- Further research and collaboration are required to refine MCID application in COPD.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...